Ajanta Pharma ends with nearly 2% gains on USFDA nod for drug

Shares of Ajanta Pharma settled with nearly 2 per cent gains today after it received final approval for its generic version of acute migraine pain relief drug almotriptan malate tablets from the US health regulator.
The stock ended the day at Rs 1,419.90, up 1.62 per cent on BSE. During the day, it jumped 3.69 per cent to Rs 1,448.80.
At NSE, shares of the company went up 1.77 per cent to close at Rs 1,421.50.
The approval by the US Food and Drug Administration (USFDA) is for multiple strengths of 6.25mg and 12.5mg of the generic version of Janssen Pharmaceuticals' Axert tablets, Ajanta Pharma said in a BSE filing yesterday.

Ajanta Pharma USA Inc, a wholly-owned subsidiary of the company, is scheduled to launch the almotriptan malate tablets in the US shortly, it said.
Almotriptan tablets is a part of an "ever growing portfolio" that the company has developed for the US market, the company added.